Last updated on July 2014

Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets FIRST

Brief description of study

Ivabradine acts by inhibiting the ionic If current that modulates the pacemaker activity of sinoatrial node cells. The aim of present study is to evaluate the efficacy and safety of IvabRadine hemisulfate Sustained-release Tablets versus placebo in patients with moderate to severe chronic systolic heart failure.

Clinical Study Identifier: NCT02188082

Contact Investigators or Research Sites near you

Start Over

Yang Jiao

The second affiliated hospital of suzhou university
Suzhou, China
  Connect »